[8-K] Turn Therapeutics Inc. Reports Material Event

Rhea-AI Filing Summary

Turn Therapeutics Inc. filed a current report to furnish a company press release under Item 7.01 (Regulation FD Disclosure). The report notes that the press release, dated January 12, 2026 and attached as Exhibit 99.1, is being treated as information that is "furnished" rather than "filed" for purposes of the Securities Exchange Act of 1934. This means it is not subject to the liability provisions of Section 18 unless the company later specifically incorporates it by reference into a Securities Act or Exchange Act filing.

false 0002023016 0002023016 2026-01-12 2026-01-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

TURN THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Delaware		001-42875		32-0456090
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

250 N. Westlake Blvd., Westlake Village, California		91362
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (818) 564-4011

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share		TTRX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01 Regulation FD Disclosure.

On January 12, 2026, Turn Therapeutics Inc., a Delaware corporation (the “Company”), issued a press release (the “Press Release”). The Press Release is furnished herewith as Exhibit 99.1.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated January 12, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 12, 2026

	TURN THERAPEUTICS INC.
	By:	/s/ Bradley Burnam
	Name:	Bradley Burnam
	Title:	Chief Executive Officer

2

FAQ

What did Turn Therapeutics (TTRX) disclose in this 8-K filing?

Turn Therapeutics Inc. reported that it issued a press release on January 12, 2026. The company furnished this press release as Exhibit 99.1 to the Form 8-K under Item 7.01, which covers Regulation FD disclosures.

How is the Turn Therapeutics (TTRX) press release treated under securities laws?

The press release attached as Exhibit 99.1 is designated as information that is furnished, not filed, under the Securities Exchange Act of 1934. As a result, it is not automatically subject to Section 18 liability unless Turn Therapeutics later states that it should be considered filed or incorporates it by reference into another Securities Act or Exchange Act filing.

What is included as an exhibit in this Turn Therapeutics (TTRX) 8-K?

The filing lists Exhibit 99.1 as a press release dated January 12, 2026. It also references Exhibit 104 as the cover page interactive data file embedded within the Inline XBRL document.

Which item of Form 8-K did Turn Therapeutics (TTRX) use for this disclosure?

The company used Item 7.01 – Regulation FD Disclosure. This item is typically used to provide broad, non-selective disclosure of information to the market in compliance with Regulation FD.

Who signed the Turn Therapeutics (TTRX) 8-K report?

The report was signed on behalf of Turn Therapeutics Inc. by Bradley Burnam, who is identified as the company’s Chief Executive Officer.